During the past decade, Policlinico Umberto I - Università "La Sapienza", Istituto Ematologia -Dipartimento di Biotecnologie Cellulari ed Ematologia conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 3 clinical trials were completed, i.e. on average, 75% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Policlinico Umberto I - Università "La Sapienza", Istituto Ematologia -Dipartimento di Biotecnologie Cellulari ed Ematologia" #1 collaborator was "AbbVie" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Policlinico Umberto I - Università "La Sapienza", Istituto Ematologia -Dipartimento di Biotecnologie Cellulari ed Ematologia" are "ALL Ph Positive" (1 trials), "Acute Lymphoblastic Leukemia" (1 trials), "Chronic Lymphocytic Leukemia" (1 trials), "Follicular Lymphoma Grade 3A" (1 trials) and "Follicular Lymphoma, Grade 1" (1 trials). Many other conditions were trialed in "Policlinico Umberto I - Università "La Sapienza", Istituto Ematologia -Dipartimento di Biotecnologie Cellulari ed Ematologia" in a lesser frequency.

Most popular intervention types in "Policlinico Umberto I - Università "La Sapienza", Istituto Ematologia -Dipartimento di Biotecnologie Cellulari ed Ematologia" are "Drug" (8 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Venetoclax" (2 trials), "Bleomycin" (1 trials), "CC-5013" (1 trials), "Clofarabine, Cyclophosphamide" (1 trials) and "Dacarbazine" (1 trials). Other intervention names were less common.

The vast majority of trials in "Policlinico Umberto I - Università "La Sapienza", Istituto Ematologia -Dipartimento di Biotecnologie Cellulari ed Ematologia" are 9 trials for "All" genders.

Currently, there are NaN active trials in "Policlinico Umberto I - Università "La Sapienza", Istituto Ematologia -Dipartimento di Biotecnologie Cellulari ed Ematologia". undefined are not yet recruiting, undefined are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Policlinico Umberto I - Università "La Sapienza", Istituto Ematologia -Dipartimento di Biotecnologie Cellulari ed Ematologia, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Policlinico Umberto I - Università "La Sapienza", Istituto Ematologia -Dipartimento di Biotecnologie Cellulari ed Ematologia, 1 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".